A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Key facts

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Principal Investigator

Ying Feng, MD

Second Affiliated Hospital of Guangzhou Medical University

Intervention

Drugs and anti-CD19 CAR transduced T cells(combination_product)

Enrollment

100 enrolled

Eligibility

14-80 years · All sexes

Timeline

2017 – 2020

Study locations (5)

• Department of Hematology, Dongguan People's Hospital, Dongguan, Guangdong, China
• Department of Hematology, the First People's Hospital of Foshan, Foshan, Guangdong, China
• Department of Hematology, Guangzhou First People's Hospital, Guangzhou, Guangdong, China
• Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
• Department of Hematology,the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Collaborators

Shenzhen Institute for Innovation and Translational Medicine · Guangzhou First People's Hospital · First People's Hospital of Foshan · Dongguan People's Hospital · The First Affiliated Hospital of Guangdong Pharmaceutical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Precursor T-cell acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07070323
  A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
  Beijing GoBroad Hospital
• RECRUITINGPHASE2NCT06648889
  Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
  Goethe University

See all trials for Precursor T-cell acute lymphoblastic leukemia →